Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Precipio ( (PRPO) ) has shared an announcement.
On November 4, 2025, Precipio, Inc. announced a Q3-2025 Shareholder Update Call scheduled for November 17, 2025. The call will provide updates on the company’s core businesses, reflecting Precipio’s ongoing commitment to transparency and stakeholder engagement. This event is significant for stakeholders as it offers insights into the company’s operational progress and strategic direction.
The most recent analyst rating on (PRPO) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Precipio stock, see the PRPO Stock Forecast page.
Spark’s Take on PRPO Stock
According to Spark, TipRanks’ AI Analyst, PRPO is a Neutral.
Precipio’s overall stock score is driven by strong technical momentum, indicating positive market sentiment. However, financial performance and valuation are constrained by ongoing profitability challenges and a negative P/E ratio. The positive earnings call sentiment is not factored into the score due to methodology constraints.
To see Spark’s full report on PRPO stock, click here.
More about Precipio
Precipio is a healthcare biotechnology company specializing in cancer diagnostics. The company aims to tackle the issue of cancer misdiagnoses by developing diagnostic products and services that enhance accuracy, improve laboratory workflows, and lead to better patient outcomes, ultimately reducing healthcare costs. Precipio’s innovative technologies are designed, tested, validated, and used clinically in their laboratory, and are later commercialized as proprietary products for the global laboratory community.
Average Trading Volume: 15,796
Technical Sentiment Signal: Hold
Current Market Cap: $32.51M
See more data about PRPO stock on TipRanks’ Stock Analysis page.